Citigroup Downgrades Pulmonx to Neutral, Lowers Price Target to $19
Citigroup analyst Joanne Wuensch downgrades Pulmonx (NASDAQ:LUNG) from Buy to Neutral and lowers the price target from $23 to $19.
Citigroup Maintains Buy on Pulmonx, Lowers Price Target to $23
Citigroup analyst Joanne Wuensch maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $32 to $23.
55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Where Pulmonx Stands With Analysts
Within the last quarter, Pulmonx (NASDAQ:LUNG) has observed the following analyst ratings:
Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $30
Morgan Stanley maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $37 to $30.
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on Wednesday.
Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $27
Wells Fargo analyst Lawrence Biegelsen maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $55 to $27.
Pulmonx Q4 EPS $(0.35) Beats $(0.36) Estimate, Sales $13.70M Miss $14.24M Estimate
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.36) by 2.78 percent. This is a 29.63 percent decrease over losses of $(0.27) per share from the same